注射液-话题@MedSci

#注射液#

122篇内容 | 2924人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1586601, encodeId=a3c41586601b7, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=Diabetologia：艾塞那肽注射液PB-119可有效治疗未治疗过的2型糖尿病, objectType=article, longId=208248, objectId=ad3e208248d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3e208248d6, replyNumber=0, likeNumber=89, createdTime=2021-03-12, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3e208248d6, moduleTitle=Diabetologia：艾塞那肽注射液PB-119可有效治疗未治疗过的2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad3e208248d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586600, encodeId=d8d81586600e7, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=超10亿大品种！齐鲁「唑来膦酸注射液」通过一致性评价, objectType=article, longId=208140, objectId=c95920814036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95920814036, replyNumber=0, likeNumber=78, createdTime=2021-03-09, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95920814036, moduleTitle=超10亿大品种！齐鲁「唑来膦酸注射液」通过一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95920814036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586603, encodeId=64551586603b3, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=72, createdTime=2021-02-28, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586599, encodeId=3ee51586599e7, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=ORL J Otorhinolaryngol Relat Spec：富血小板血浆注射液对萎缩性鼻炎患者的影响 , objectType=article, longId=207566, objectId=cd1a20e566bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd1a20e566bc, replyNumber=0, likeNumber=93, createdTime=2021-02-26, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd1a20e566bc, moduleTitle=ORL J Otorhinolaryngol Relat Spec：富血小板血浆注射液对萎缩性鼻炎患者的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd1a20e566bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586598, encodeId=5268158659826, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录, objectType=article, longId=204978, objectId=edf02049e8ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf02049e8ca, replyNumber=0, likeNumber=0, createdTime=2020-12-31, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf02049e8ca, moduleTitle=我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf02049e8ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586597, encodeId=2663158659e3e, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=全球**皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药, objectType=article, longId=204434, objectId=6b8c20443418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b8c20443418, replyNumber=0, likeNumber=65, createdTime=2020-12-14, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b8c20443418, moduleTitle=全球**皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b8c20443418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586596, encodeId=b22c15865968c, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=苑东生物「格隆溴铵注射液」即将第2家获批, objectType=article, longId=202182, objectId=099a2021824f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099a2021824f, replyNumber=0, likeNumber=85, createdTime=2020-10-17, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099a2021824f, moduleTitle=苑东生物「格隆溴铵注射液」即将第2家获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099a2021824f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586595, encodeId=7e3e1586595ad, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, objectType=article, longId=201941, objectId=0be8201941c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be8201941c7, replyNumber=0, likeNumber=62, createdTime=2020-10-12, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be8201941c7, moduleTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be8201941c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=君实生物重组全人源抗SARS-CoV-2单克隆抗体注射液进展良好, objectType=article, longId=201858, objectId=635420185860, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=635420185860, replyNumber=0, likeNumber=90, createdTime=2020-10-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=635420185860, moduleTitle=君实生物重组全人源抗SARS-CoV-2单克隆抗体注射液进展良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=635420185860)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586593, encodeId=be07158659307, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, objectType=article, longId=201078, objectId=94a22010e8b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94a22010e8b1, replyNumber=0, likeNumber=80, createdTime=2020-09-24, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94a22010e8b1, moduleTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94a22010e8b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586592, encodeId=a55e158659220, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=亨特综合征新药「艾度硫酸酯酶β注射液」在中国获批, objectType=article, longId=200288, objectId=8e652002888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e652002888f, replyNumber=0, likeNumber=69, createdTime=2020-09-06, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e652002888f, moduleTitle=亨特综合征新药「艾度硫酸酯酶β注射液」在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e652002888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586591, encodeId=8ad2158659195, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=第三款国产阿达木单抗注射液获批上市, objectType=article, longId=200239, objectId=18dc200239fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18dc200239fd, replyNumber=0, likeNumber=136, createdTime=2020-09-05, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18dc200239fd, moduleTitle=第三款国产阿达木单抗注射液获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18dc200239fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586590, encodeId=7c3d158659003, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, objectType=article, longId=199076, objectId=63ee1990e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ee1990e68c, replyNumber=0, likeNumber=75, createdTime=2020-08-11, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ee1990e68c, moduleTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ee1990e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586589, encodeId=2417158658904, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=Crit Care Med：血必净注射液治疗重症社区获得性肺炎危重病人的效果, objectType=article, longId=198200, objectId=e87419820005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e87419820005, replyNumber=0, likeNumber=0, createdTime=2020-07-30, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e87419820005, moduleTitle=Crit Care Med：血必净注射液治疗重症社区获得性肺炎危重病人的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e87419820005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586588, encodeId=0bcf15865883a, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=Endoscopy：凝血酶和氰基丙烯酸酯注射液在控制急性胃静脉曲张出血中的作用, objectType=article, longId=196960, objectId=5fd01969609a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd01969609a, replyNumber=0, likeNumber=66, createdTime=2020-07-04, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd01969609a, moduleTitle=Endoscopy：凝血酶和氰基丙烯酸酯注射液在控制急性胃静脉曲张出血中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd01969609a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586587, encodeId=1ee8158658edc, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=J Oral Facial Pain Headache：富血小板血浆注射液对颞下颌关节骨关节炎患者疼痛减轻的效果, objectType=article, longId=196534, objectId=8ffa1965345a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ffa1965345a, replyNumber=0, likeNumber=72, createdTime=2020-06-27, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ffa1965345a, moduleTitle=J Oral Facial Pain Headache：富血小板血浆注射液对颞下颌关节骨关节炎患者疼痛减轻的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ffa1965345a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586586, encodeId=ae4a1586586cd, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=JITC：中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, objectType=article, longId=193417, objectId=b9b319341e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9b319341e19, replyNumber=0, likeNumber=64, createdTime=2020-05-04, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9b319341e19, moduleTitle=JITC：中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9b319341e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586585, encodeId=a007158658584, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=美国将禁止关键医疗物资的出口；帕立骨化醇注射液再赢劲敌, objectType=article, longId=192288, objectId=9de619228828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de619228828, replyNumber=0, likeNumber=76, createdTime=2020-04-16, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de619228828, moduleTitle=美国将禁止关键医疗物资的出口；帕立骨化醇注射液再赢劲敌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de619228828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586584, encodeId=6e8515865849a, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=J Immunother Cancer：营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, objectType=article, longId=191141, objectId=07ec191141e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ec191141e3, replyNumber=0, likeNumber=91, createdTime=2020-04-01, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ec191141e3, moduleTitle=J Immunother Cancer：营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ec191141e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586583, encodeId=f91c15865831e, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知, objectType=article, longId=190911, objectId=623b190911ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623b190911ab, replyNumber=0, likeNumber=86, createdTime=2020-03-28, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623b190911ab, moduleTitle=关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623b190911ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

注射液

2020-05-29

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

Diabetologia：艾塞那肽注射液PB-119可有效治疗未治疗过的2型糖尿病

2021-03-12

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

超10亿大品种！齐鲁「唑来膦酸注射液」通过一致性评价

2021-03-09

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-02-28

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

ORL J Otorhinolaryngol Relat Spec：富血小板血浆注射液对萎缩性鼻炎患者的影响

2021-02-26

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录

2020-12-31

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

全球**皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药

2020-12-14

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

苑东生物「格隆溴铵注射液」即将第2家获批

2020-10-17

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤

2020-10-12

智智灵药 (审核中...)

前往app查看评论内容

#注射液#

君实生物重组全人源抗SARS-CoV-2单克隆抗体注射液进展良好

2020-10-10

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择

2020-09-24

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

亨特综合征新药「艾度硫酸酯酶β注射液」在中国获批

2020-09-06

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

第三款国产阿达木单抗注射液获批上市

2020-09-05

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人

2020-08-11

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

Crit Care Med：血必净注射液治疗重症社区获得性肺炎危重病人的效果

2020-07-30

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

Endoscopy：凝血酶和氰基丙烯酸酯注射液在控制急性胃静脉曲张出血中的作用

2020-07-04

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

J Oral Facial Pain Headache：富血小板血浆注射液对颞下颌关节骨关节炎患者疼痛减轻的效果

2020-06-27

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

JITC：中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

2020-05-04

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

美国将禁止关键医疗物资的出口；帕立骨化醇注射液再赢劲敌

2020-04-16

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

J Immunother Cancer：营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

2020-04-01

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知

2020-03-28

科室
- - 订阅+
  - 更多科室
工具
服务